QuiaPEG

About

 
Board of directors
Management team
Company overview

Company overview 

QuiaPEG Pharmaceuticals AB is an emerging biotech company developing biopharmaceuticals based on a proprietary, cutting-edge PEGylation technology platform. The company´s technology is applicable on proteins, peptides and small molecules and offers a unique half-life extension platform. The technology offers improved patient convenience, new patent lives and a substantial reduction in cost-of-goods.

The company is initially developing novel long-acting biopharmaceuticals for the treatment of metabolic disorders using the company´s proprietary technology platform. The company´s lead project is intended to reduce the burden of frequent injection therapy by requiring significantly fewer injections, potentially improving compliance and yielding better treatment outcomes.

The company was founded in 2012 and is headquartered at Karolinska Institutet Science Park, Stockholm, Sweden.

 

Our mission 

QuiaPEG Pharmaceuticals develops improved versions of clinically validated drugs by using its proprietary PEGylation technology. The mission is to create new proprietary drugs enhancing patient convenience and compliance.

Contact
QuiaPEG Pharmaceuticals Holding AB

Visiting address

Karolinska Institutet Science Park
Fogdevreten 2
171 65 Solna
+46 (0) 70 693 12 53
info@quiapeg.com

Postal adress

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46-70-693 1253
Send a message